{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T05:24:51Z","timestamp":1787462691751,"version":"build-2736575974"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40265-026-02325-x","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:56:35Z","timestamp":1778342195000},"page":"1013-1032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map"],"prefix":"10.1007","volume":"86","author":[{"given":"Mojca","family":"Jensterle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6594-5254","authenticated-orcid":false,"given":"Andrej","family":"Janez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"12","key":"2325_CR1","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.4158\/EP15748.DSCPT2","volume":"21","author":"NF Goodman","year":"2015","unstructured":"Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome\u2014part 2. Endocr Pract. 2015;21(12):1415\u201326.","journal-title":"Endocr Pract"},{"key":"2325_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CLEP.S37559","volume":"6","author":"S Sirmans","year":"2013","unstructured":"Sirmans S, Pate K. Epidemiology, diagnosis, and management of polycystic ovary syndrome. CLEP. 2013;6:1\u201313.","journal-title":"CLEP"},{"issue":"6","key":"2325_CR3","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/humupd\/dms030","volume":"18","author":"SS Lim","year":"2012","unstructured":"Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(6):618\u201337.","journal-title":"Hum Reprod Update"},{"issue":"12","key":"2325_CR4","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1210\/jc.2013-2350","volume":"98","author":"RS Legro","year":"2013","unstructured":"Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565\u201392.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2325_CR5","doi-asserted-by":"publisher","first-page":"085","DOI":"10.1055\/s-2007-992928","volume":"26","author":"L Moran","year":"2008","unstructured":"Moran L, Brinkworth G, Norman R. Dietary therapy in polycystic ovary syndrome. Semin Reprod Med. 2008;26(1):085\u201392.","journal-title":"Semin Reprod Med"},{"issue":"9","key":"2325_CR6","first-page":"2586","volume":"80","author":"J Holte","year":"1995","unstructured":"Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995;80(9):2586\u201393.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2325_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/humrep\/deac267","volume":"38","author":"CL Haase","year":"2023","unstructured":"Haase CL, Varbo A, Laursen PN, Schnecke V, Balen AH. Association between body mass index, weight loss and the chance of pregnancy in women with polycystic ovary syndrome and overweight or obesity: a retrospective cohort study in the UK. Hum Reprod. 2023;38(3):471\u201381.","journal-title":"Hum Reprod"},{"issue":"10","key":"2325_CR8","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1210\/clinem\/dgad463","volume":"108","author":"HJ Teede","year":"2023","unstructured":"Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108(10):2447\u201369.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2325_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2325_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/17446651.2025.2554668","volume":"20","author":"M Jensterle","year":"2025","unstructured":"Jensterle M, Janez A. Reframing polycystic ovary syndrome as a complication of obesity: the evolving role of incretin-based therapies. Expert Rev Endocrinol Metab. 2025;20(6):445\u20138.","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"4","key":"2325_CR11","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/humupd\/dmz019","volume":"25","author":"M Jensterle","year":"2019","unstructured":"Jensterle M, Janez A, Fliers E, DeVries JH, Vrtacnik-Bokal E, Siegelaar SE. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum Reprod Update. 2019;25(4):504\u201317.","journal-title":"Hum Reprod Update"},{"issue":"1","key":"2325_CR12","doi-asserted-by":"publisher","first-page":"8498","DOI":"10.1038\/s41467-024-52898-y","volume":"15","author":"MA S\u00e1nchez-Garrido","year":"2024","unstructured":"S\u00e1nchez-Garrido MA, Serrano-L\u00f3pez V, Ruiz-Pino F, V\u00e1zquez MJ, Rodr\u00edguez-Mart\u00edn A, Torres E, et al. Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy. Nat Commun. 2024;15(1):8498.","journal-title":"Nat Commun"},{"issue":"3","key":"2325_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-13-0797","volume":"170","author":"M Jensterle Sever","year":"2014","unstructured":"Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014;170(3):451\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2325_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3109\/07435800.2014.966385","volume":"40","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Kocjan T, Kravos NA, Pfeifer M, Janez A. Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome. Endocr Res. 2015;40(3):133\u20138.","journal-title":"Endocr Res"},{"key":"2325_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2014.00140\/abstract","author":"CB Rasmussen","year":"2014","unstructured":"Rasmussen CB, Lindenberg S. The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study. Front Endocrinol. 2014. https:\/\/doi.org\/10.3389\/fendo.2014.00140\/abstract.","journal-title":"Front Endocrinol"},{"issue":"1","key":"2325_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-18-0175","volume":"179","author":"V Salamun","year":"2018","unstructured":"Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179(1):1\u201311.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2325_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/cen.12369","volume":"81","author":"H Kahal","year":"2014","unstructured":"Kahal H, Abouda G, Rigby AS, Coady AM, Kilpatrick ES, Atkin SL. Glucagon\u2010like peptide\u20101 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2014;81(4):523\u20138.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2325_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF03401383","volume":"14","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens). 2015;14(1):81\u201390.","journal-title":"Hormones (Athens)"},{"issue":"7","key":"2325_CR19","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00228-015-1868-1","volume":"71","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Pir\u0161 B, Gori\u010dar K, Dol\u017ean V, Jane\u017e A. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study. Eur J Clin Pharmacol. 2015;71(7):817\u201324.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2325_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-015-0161-3","volume":"8","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res. 2015;8(1):32.","journal-title":"J Ovarian Res"},{"issue":"1","key":"2325_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-015-0005-6","volume":"15","author":"H Kahal","year":"2015","unstructured":"Kahal H, Aburima A, Ungvari T, Rigby AS, Coady AM, Vince RV, et al. The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. BMC Endocr Disord. 2015;15(1):14.","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"2325_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/EC-16-0113","volume":"6","author":"M Nylander","year":"2017","unstructured":"Nylander M, Fr\u00f8ssing S, Kistorp C, Faber J, Skouby SO. Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential. Endocr Connect. 2017;6(2):89\u201399.","journal-title":"Endocr Connect"},{"issue":"1","key":"2325_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.rbmo.2017.03.023","volume":"35","author":"M Nylander","year":"2017","unstructured":"Nylander M, Fr\u00f8ssing S, Clausen HV, Kistorp C, Faber J, Skouby SO. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017;35(1):121\u20137.","journal-title":"Reprod Biomed Online"},{"issue":"1","key":"2325_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dom.13053","volume":"20","author":"S Fr\u00f8ssing","year":"2018","unstructured":"Fr\u00f8ssing S, Nylander M, Chabanova E, Frystyk J, Holst JJ, Kistorp C, et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial. Diabetes Obes Metab. 2018;20(1):215\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2325_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1530\/EC-17-0327","volume":"7","author":"S Fr\u00f8ssing","year":"2018","unstructured":"Fr\u00f8ssing S, Nylander M, Kistorp C, Skouby SO, Faber J. Effect of Liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS. Endocr Connect. 2018;7(1):115\u201323.","journal-title":"Endocr Connect"},{"issue":"3","key":"2325_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1620\/tjem.2025.J009","volume":"266","author":"L Su","year":"2025","unstructured":"Su L, Hao X, Lu W. Effects of Liraglutide on leptin promoter methylation in ovarian granulosa cells of obese Polycystic Ovary Syndrome patients. Tohoku J Exp Med. 2025;266(3):199\u2013207.","journal-title":"Tohoku J Exp Med"},{"issue":"4","key":"2325_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, L\u00fcdemann J, Andreassen C, Navarria A, et al. Semaglutide versus Dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275\u201386.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2325_CR28","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","volume":"7","author":"I Lingvay","year":"2019","unstructured":"Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, Le Roux CW, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834\u201344.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2325_CR29","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356\u201367.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2325_CR30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","volume":"46","author":"MS Capehorn","year":"2020","unstructured":"Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100\u20139.","journal-title":"Diabetes Metab"},{"issue":"9","key":"2325_CR31","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/dom.14765","volume":"24","author":"M Kellerer","year":"2022","unstructured":"Kellerer M, Kaltoft MS, Lawson J, Nielsen LL, Strojek K, Tabak \u00d6, et al. Effect of once\u2010weekly semaglutide versus thrice\u2010daily insulin aspart, both as add\u2010on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open\u2010label, multinational, phase 3b trial. Diabetes Obes Metab. 2022;24(9):1788\u201399.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2325_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","volume":"9","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Auerbach P, Bajaj HS, Fukushima Y, Lingvay I, Macura S, et al. Efficacy and safety of once-weekly semaglutide 2\u00b70 mg versus 1\u00b70 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563\u201374.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2325_CR33","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1210\/clinem\/dgaf278","volume":"111","author":"M Jensterle","year":"2025","unstructured":"Jensterle M, Kovac J, Vovk A, Ferjan S, Battelino S, Battelino T, et al. Semaglutide and taste in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled study. J Clin Endocrinol Metab. 2025;111(1):e270\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"2325_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108935","volume":"178","author":"M Jensterle","year":"2021","unstructured":"Jensterle M, Ferjan S, Vovk A, Battelino T, Rizzo M, Jane\u017e A. Semaglutide reduces fat accumulation in the tongue: a randomized single-blind, pilot study. Diabetes Res Clin Pract. 2021;178:108935.","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"2325_CR35","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/dom.14944","volume":"25","author":"M Jensterle","year":"2023","unstructured":"Jensterle M, Ferjan S, Le\u017eai\u010d L, So\u010dan A, Gori\u010dar K, Zaletel K, et al. Semaglutide delays 4\u2010hour gastric emptying in women with Polycystic Ovary Syndrome and obesity. Diabetes Obes Metab. 2023;25(4):975\u201384.","journal-title":"Diabetes Obes Metab"},{"issue":"18","key":"2325_CR36","doi-asserted-by":"publisher","first-page":"5921","DOI":"10.3390\/jcm12185921","volume":"12","author":"E Carmina","year":"2023","unstructured":"Carmina E, Longo RA. Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs. JCM. 2023;12(18):5921.","journal-title":"JCM"},{"issue":"1","key":"2325_CR37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12958-025-01447-3","volume":"23","author":"H Chen","year":"2025","unstructured":"Chen H, Lei X, Yang Z, Xu Y, Liu D, Wang C, et al. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight\/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. Reprod Biol Endocrinol. 2025;23(1):108.","journal-title":"Reprod Biol Endocrinol"},{"issue":"11","key":"2325_CR38","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"10278","key":"2325_CR39","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384.","journal-title":"Lancet"},{"issue":"14","key":"2325_CR40","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403.","journal-title":"JAMA"},{"issue":"14","key":"2325_CR41","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414.","journal-title":"JAMA"},{"issue":"2","key":"2325_CR42","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138.","journal-title":"JAMA"},{"issue":"10","key":"2325_CR43","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of Semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083\u201391.","journal-title":"Nat Med"},{"issue":"24","key":"2325_CR44","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","volume":"387","author":"D Weghuber","year":"2022","unstructured":"Weghuber D, Barrett T, Barrientos-P\u00e9rez M, Gies I, Hesse D, Jeppesen OK, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245\u201357.","journal-title":"N Engl J Med"},{"issue":"12","key":"2325_CR45","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"24","key":"2325_CR46","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"key":"2325_CR47","unstructured":"ClinicalTrials.gov. Semaglutide vs metformin in polycystic ovary syndrome. Updated October 11, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05646199. Accessed 29 Nov 2023."},{"key":"2325_CR48","unstructured":"ClinicalTrials.gov. Role of semaglutide in restoring ovulation in youth and adults with polycystic ovary syndrome. Updated November 24, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05819853. Accessed 29 Nov 2023."},{"key":"2325_CR49","unstructured":"ClinicalTrials.gov. Semaglutide improves metabolic abnormalities and fertility in obese infertile women with polycystic ovary syndrome. Updated March 25, 2024. https:\/\/clinicaltrials.gov\/study\/NCT05702905. Accessed 2 Apr 2024."},{"key":"2325_CR50","unstructured":"ClinicalTrials.gov. Semaglutide and polycystic ovarian syndrome: an emerging treatment strategy. Updated March 27, 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT06222437. Accessed 11 Apr 2024."},{"issue":"9","key":"2325_CR51","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724\u201332.","journal-title":"Diabetes Care"},{"issue":"12","key":"2325_CR52","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2337\/dc19-0883","volume":"42","author":"HW Rodbard","year":"2019","unstructured":"Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg S\u00d8, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272\u201381.","journal-title":"Diabetes Care"},{"issue":"15","key":"2325_CR53","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jama.2019.2942","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466.","journal-title":"JAMA"},{"issue":"10192","key":"2325_CR54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","volume":"394","author":"R Pratley","year":"2019","unstructured":"Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, et al. Oral semaglutide versus subcutaneous Liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39\u201350.","journal-title":"Lancet"},{"issue":"7","key":"2325_CR55","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515\u201327.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2325_CR56","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"7","key":"2325_CR57","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","volume":"7","author":"TR Pieber","year":"2019","unstructured":"Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528\u201339.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2325_CR58","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.2337\/dc19-0898","volume":"42","author":"B Zinman","year":"2019","unstructured":"Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262\u201371.","journal-title":"Diabetes Care"},{"issue":"5","key":"2325_CR59","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","volume":"8","author":"Y Yamada","year":"2020","unstructured":"Yamada Y, Katagiri H, Hamamoto Y, Deenadayalan S, Navarria A, Nishijima K, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, controlled trial. Lancet Diabetes Endocrinol. 2020;8(5):377\u201391.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2325_CR60","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","volume":"8","author":"D Yabe","year":"2020","unstructured":"Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2020;8(5):392\u2013406.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10403","key":"2325_CR61","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","volume":"402","author":"VR Aroda","year":"2023","unstructured":"Aroda VR, Aberle J, Bardtrum L, Christiansen E, Knop FK, Gabery S, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet. 2023;402(10403):693\u2013704.","journal-title":"Lancet"},{"key":"2325_CR62","unstructured":"An investigator-sponsored study is evaluating the effects of oral semaglutide compared to dietary intervention on changes in hepatic fat fraction and body weight in patients aged 12 to 21 years with obesity and PCOS. For additional information, please refer to clinicaltrials.gov (NCT03919929)."},{"issue":"10295","key":"2325_CR63","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, Kaneko S, Lee CJ, Fern\u00e1ndez Land\u00f3 L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143\u201355.","journal-title":"Lancet"},{"issue":"6","key":"2325_CR64","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"10300","key":"2325_CR65","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, Frias JP, Fern\u00e1ndez Land\u00f3 L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583\u201398.","journal-title":"Lancet"},{"issue":"10313","key":"2325_CR66","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811\u201324.","journal-title":"Lancet"},{"issue":"6","key":"2325_CR67","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534.","journal-title":"JAMA"},{"issue":"3","key":"2325_CR68","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"10402","key":"2325_CR69","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, Le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613\u201326.","journal-title":"Lancet"},{"issue":"11","key":"2325_CR70","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909\u201318.","journal-title":"Nat Med"},{"issue":"1","key":"2325_CR71","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38.","journal-title":"JAMA"},{"issue":"2","key":"2325_CR72","doi-asserted-by":"publisher","first-page":"37","DOI":"10.11648\/j.ijde.20251002.12","volume":"10","author":"J Ferdous","year":"2025","unstructured":"Ferdous J, Hossain M, Faika M, Begum M, Mahjabeen S, Jahan I, et al. Role of tirzepatide in obesity management among women with polycystic ovary syndrome. IJDE. 2025;10(2):37\u201344.","journal-title":"IJDE."},{"issue":"3","key":"2325_CR73","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00404-015-3976-7","volume":"293","author":"M Niafar","year":"2016","unstructured":"Niafar M, Pourafkari L, Porhomayon J, Nader N. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Arch Gynecol Obstet. 2016;293(3):509\u201315.","journal-title":"Arch Gynecol Obstet"},{"issue":"10","key":"2325_CR74","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1111\/obr.12720","volume":"19","author":"FF Wang","year":"2018","unstructured":"Wang FF, Wu Y, Zhu YH, Ding T, Batterham RL, Qu F, et al. Pharmacologic therapy to induce weight loss in women who have obesity\/overweight with Polycystic Ovary Syndrome: a systematic review and network meta-analysis. Obes Rev. 2018;19(10):1424\u201345.","journal-title":"Obes Rev"},{"issue":"2","key":"2325_CR75","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.rbmo.2019.04.017","volume":"39","author":"Y Han","year":"2019","unstructured":"Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online. 2019;39(2):332\u201342.","journal-title":"Reprod Biomed Online"},{"issue":"9","key":"2325_CR76","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1210\/clinem\/dgaa337","volume":"105","author":"C Xing","year":"2020","unstructured":"Xing C, Li C, He B. Insulin sensitizers for improving the endocrine and metabolic profile in overweight women with PCOS. J Clin Endocrinol Metab. 2020;105(9):2950\u201363.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2021","key":"2325_CR77","first-page":"6616693","volume":"13","author":"X Lyu","year":"2021","unstructured":"Lyu X, Lyu T, Wang X, Zhu H, Pan H, Wang L, et al. The antiobesity effect of GLP-1 receptor agonists alone or in combination with metformin in overweight\/obese women with PCOS: a systematic review and meta-analysis. Int J Endocrinol. 2021;13(2021):6616693.","journal-title":"Int J Endocrinol."},{"issue":"3","key":"2325_CR78","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/cen.14623","volume":"96","author":"MA Abdalla","year":"2022","unstructured":"Abdalla MA, Shah N, Deshmukh H, Sahebkar A, \u00d6stlundh L, Al-Rifai RH, et al. Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Endocrinol (Oxf). 2022;96(3):371\u201394.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2325_CR79","doi-asserted-by":"publisher","first-page":"542","DOI":"10.23736\/S0026-4806.21.07085-3","volume":"113","author":"D Tian","year":"2022","unstructured":"Tian D, Chen W, Xu Q, Li X, Lv Q. Liraglutide monotherapy and add-on therapy in obese women with polycystic ovarian syndrome: a systematic review and meta-analysis. Minerva Med. 2022;113(3):542\u201350.","journal-title":"Minerva Med"},{"issue":"2","key":"2325_CR80","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40618-021-01666-6","volume":"45","author":"JJ Ge","year":"2022","unstructured":"Ge JJ, Wang DJ, Song W, Shen SM, Ge WH. The effectiveness and safety of liraglutide in treating overweight\/obese patients with polycystic ovary syndrome: a meta-analysis. J Endocrinol Invest. 2022;45(2):261\u201373.","journal-title":"J Endocrinol Invest"},{"issue":"23","key":"2325_CR81","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12902-023-01500-5","volume":"8","author":"L Zhou","year":"2023","unstructured":"Zhou L, Qu H, Yang L, Shou L. Effects of GLP-1 receptor agonists on pregnancy rate and menstrual cyclicity in women with PCOS: a meta-analysis and systematic review. BMC Endocr Disord. 2023;8(23):245.","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"2325_CR82","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13704","volume":"25","author":"A Goldberg","year":"2024","unstructured":"Goldberg A, Graca S, Liu J, Rao V, Witchel SF, Pena A, et al. Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obes Rev. 2024;25(5):e13704.","journal-title":"Obes Rev"},{"issue":"10","key":"2325_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2024.108834","volume":"38","author":"BA de Hollanda Morais","year":"2024","unstructured":"de Hollanda Morais BA, Martins Priz\u00e3o V, de Moura de Souza M, Ximenes Mendes B, Rodrigues Defante ML, Cosendey Martins O, et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis of randomized controlled trials. J Diabetes Complic. 2024;38(10):108834.","journal-title":"J Diabetes Complic"},{"issue":"1","key":"2325_CR84","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13098-025-01730-8","volume":"17","author":"K Sridharan","year":"2025","unstructured":"Sridharan K, Sivaramakrishnan G. Expanding therapeutic horizons: GLP-1 receptor agonists and SGLT2 inhibitors in PCOS: systematic review and network meta-analysis. Diabetol Metab Syndr. 2025;17(1):168.","journal-title":"Diabetol Metab Syndr"},{"issue":"15","key":"2325_CR85","doi-asserted-by":"publisher","first-page":"16512","DOI":"10.1038\/s41598-025-99622-4","volume":"13","author":"S Lin","year":"2025","unstructured":"Lin S, Deng Y, Huang J, Li M, Sooranna SR, Qin M, et al. Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis. Sci Rep. 2025;13(15):16512.","journal-title":"Sci Rep"},{"issue":"25","key":"2325_CR86","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12905-025-03594-6","volume":"15","author":"Y Bo","year":"2025","unstructured":"Bo Y, Zhao J, Liu C, Yu T. Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in PCOS: a network meta-analysis. BMC Womens Health. 2025;15(25):64.","journal-title":"BMC Womens Health"},{"issue":"5","key":"2325_CR87","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s43032-025-01788-9","volume":"32","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Jiang L, Li N, Cao J, Pi J. GLP-1 receptor agonists combined with metformin versus metformin alone in PCOS: a meta-analysis. Reprod Sci. 2025;32(5):1661\u201375.","journal-title":"Reprod Sci"},{"issue":"25","key":"2325_CR88","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12905-025-03787-z","volume":"6","author":"R Huang","year":"2025","unstructured":"Huang R, He Y. The safety and efficacy of liraglutide combined with metformin in PCOS: a meta-analysis. BMC Womens Health. 2025;6(25):282.","journal-title":"BMC Womens Health"},{"issue":"11","key":"2325_CR89","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1111\/dom.70028","volume":"27","author":"J Ling","year":"2025","unstructured":"Ling J, Wang T, Huang W, Zhen Y, Zhang M, Fang X, et al. Combined liraglutide and metformin therapy in overweight or obese women with PCOS: a systematic review and meta-analysis. Diabetes Obes Metab. 2025;27(11):6139\u201353.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2325_CR90","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/ejendo\/lvag033","volume":"194","author":"M Forslund","year":"2026","unstructured":"Forslund M, W\u00e4ndell P, Forsberg L, \u00d6sterberg M, Dagerhamn J, Wernersson E, et al. GLP-1 receptor agonist treatment in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol. 2026;194(3):25\u201339.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2325_CR91","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1111\/dom.70452","volume":"28","author":"YT Lu","year":"2026","unstructured":"Lu YT, Chang PH, Chen HJ, Hsueh YW, Chang CW, Hsu HC, et al. Efficacy of liraglutide on metabolic and reproductive outcomes in women with PCOS: a systematic review and meta-analysis. Diabetes Obes Metab. 2026;28(4):2523\u201335.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2325_CR92","doi-asserted-by":"publisher","first-page":"2553052","DOI":"10.1080\/09513590.2025.2553052","volume":"41","author":"W Chen","year":"2025","unstructured":"Chen W, Xu D, Shao X, Song Q, Chen R. Meta-analysis of the effects of semaglutide on BMI and lipid levels in PCOS patients. Gynecol Endocrinol. 2025;41(1):2553052.","journal-title":"Gynecol Endocrinol"},{"key":"2325_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2025.102038","author":"A Koceva","year":"2025","unstructured":"Koceva A, Jane\u017e A, Jensterle M. Preconception use of GLP-1 and GLP-1\/GIP receptor agonists for obesity treatment. Best Pract Res Clin Endocrinol Metab. 2025. https:\/\/doi.org\/10.1016\/j.beem.2025.102038.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2325_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2025.01.019","author":"MR Imbroane","year":"2025","unstructured":"Imbroane MR, LeMoine F, Nau CT. Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes. Am J Obstet Gynecol. 2025. https:\/\/doi.org\/10.1016\/j.ajog.2025.01.019.","journal-title":"Am J Obstet Gynecol"},{"key":"2325_CR95","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1001\/jama.2025.20951","volume":"334","author":"J Maya","year":"2025","unstructured":"Maya J, Pant D, Fu Y, James K, Batlle C, Hsu S, et al. Gestational weight gain and pregnancy outcomes after GLP-1 receptor agonist discontinuation. JAMA. 2025;334:2186\u201396.","journal-title":"JAMA"},{"issue":"13","key":"2325_CR96","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193\u2013205.","journal-title":"N Engl J Med"},{"issue":"17","key":"2325_CR97","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S, Udd\u00e9n Hemmingsson J, Hjelmes\u00e6th J, Hoffmann Morville T, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391(17):1573\u201383.","journal-title":"N Engl J Med"},{"issue":"1","key":"2325_CR98","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41387-025-00382-x","volume":"15","author":"EJ Dhurandhar","year":"2025","unstructured":"Dhurandhar EJ, Maki KC, Dhurandhar NV, Kyle TK, Yurkow S, Hawkins MAW, et al. Food noise: definition, measurement, and future research directions. Nutr Diabetes. 2025;15(1):30.","journal-title":"Nutr Diabetes"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02325-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02325-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02325-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T08:14:59Z","timestamp":1782202499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02325-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":98,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2325"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02325-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.J. reports receiving lecture honoraria from Novo Nordisk, Eli Lilly, Pfizer, Amgen, AstraZeneca, Novartis and Sanofi and being an advisory board member of Novo Nordisk, Eli Lilly, Amgen and Pfizer. A.J. has served as a consultant and is on Speakers Bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Abbott, Novo Nordisk, Medtronic, and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MJ and AJ screened the abstracts, assessed full-text and contributed equally to the conception. MJ prepared the first draft. MJ and AJ revised and approved the final version of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}